Path ID: DB00922_MESH_D006333_2

db00922-mesh-d006333-2

Concepts

Identifier Name Type
MESH:C076731 Levosimendan Drug
UniProt:Q14432 cGMP-inhibited 3’,5’-cyclic phosphodiesterase A Protein
CHEBI:17489 3’,5’-cyclic AMP ChemicalSubstance
GO:0004679 AMP-activated protein kinase activity MolecularActivity
GO:0005262 Calcium channel activity MolecularActivity
GO:0070509 Calcium ion import BiologicalProcess
GO:0060047 Heart contraction BiologicalProcess
GO:0044557 Relaxation of smooth muscle BiologicalProcess
GO:0042311 Vasodilation BiologicalProcess
HP:0000822 Hypertension PhenotypicFeature
MESH:D006333 Congestive heart failure Disease

Relationships

NOTE: predicates are annotated in Biolink Model (v1.3.0)

Subject Predicate Object
Levosimendan DECREASES ACTIVITY OF Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase A
Cgmp-Inhibited 3’,5’-Cyclic Phosphodiesterase A DECREASES ABUNDANCE OF 3’,5’-Cyclic Amp
3’,5’-Cyclic Amp POSITIVELY REGULATES Amp-Activated Protein Kinase Activity
Amp-Activated Protein Kinase Activity POSITIVELY REGULATES Calcium Channel Activity
Calcium Channel Activity POSITIVELY REGULATES Calcium Ion Import
Calcium Ion Import POSITIVELY REGULATES Heart Contraction
Heart Contraction NEGATIVELY CORRELATED WITH Congestive Heart Failure
3’,5’-Cyclic Amp POSITIVELY REGULATES Relaxation Of Smooth Muscle
Relaxation Of Smooth Muscle POSITIVELY REGULATES Vasodilation
Vasodilation NEGATIVELY CORRELATED WITH Hypertension
Hypertension AFFECTS RISK FOR Congestive Heart Failure

Comment: Levosimendan has not been approved for use in the U.S. or Canada. It has been reported that levosimendan may act preferentially as a Ca2+ sensitizer at lower concentrations, whereas at higher concentrations its action as a PDE-III inhibitor becomes more prominent in experimental animals and humans.

Reference: